Litigation Details for Astellas Pharma Inc. v. Sandoz Inc. (D. Del. 2020)
✉ Email this page to a colleague
Astellas Pharma Inc. v. Sandoz Inc. (D. Del. 2020)
| Docket | ⤷ Subscribe | Date Filed | 2020-11-24 |
| Court | District Court, D. Delaware | Date Terminated | 2023-06-09 |
| Cause | 35:271 Patent Infringement | Assigned To | Joseph F. Bataillon |
| Jury Demand | Plaintiff | Referred To | Christopher J. Burke |
| Parties | AUROBINDO PHARMA LTD. | ||
| Patents | 6,346,532; 6,562,375; 7,342,117; 7,982,049; 8,772,315; 8,835,474; 9,056,120; RE44,872 | ||
| Attorneys | Lance A. Soderstrom | ||
| Firms | Stamoulis & Weinblatt LLC | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Astellas Pharma Inc. v. Sandoz Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe , ⤷ Subscribe , and ⤷ Subscribe .
Details for Astellas Pharma Inc. v. Sandoz Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-11-24 | 1 | Complaint | Book listed patent for Myrbetriq® Tablets, United States Patent No. 6,346,532 (“the ’532 Patent”) against… action for patent infringement of United States Patent No. 10,842,780 (“the ’780 Patent”), arising under…7,342,117 (“the ’117 Patent”), 7,982,049 (“the ’049 Patent”), 8,835,474 (“the ’474 Patent”) and RE44,872 (“the…the then-listed patents in the Orange Book for Myrbetriq® Tablets, United States Patent Nos. 7,342,117… the ’780 Patent because, inter alia, they concluded before the issuance of the ’780 Patent. | External link to document |
| 2023-02-21 | 523 | Redacted Document | accompanying Paragraph IV certification for U.S. Patent Nos. 7,342,117; 7,982,049; …accompanying Paragraph IV certification for U.S. Patent Nos. 7,342,117, 7,982,049, 8,835,474, and RE44,872 …, journal, patent, patent publication, certified file history of a patent or patent application, or… infringement of United States Patent No. 10,842,780 (“the ’780 Patent”) based on Sandoz’s September…infringement of United States Patent No. 10,842,780 (“the ’780 Patent”) based on Sandoz’s September | External link to document |
| 2023-06-09 | 571 | Order - Memorandum and Order | having been long known, e.g., U.S. Pat. No. 6,346,532; Astellas Pharma Inc. v. Actavis Elizabeth …MEMORANDUM AND ORDER, claims 5, 20, and 25 of U.S. Patent No. 10,842,780 are invalid. All pending motions…matter is before the Court for final decision on patent-infringement charges arising under the Hatch-Waxman…the heels of a previous suit involving different patents but the same Abbreviated New Drug Applications…contrasted by its inefficacy on a full one—U.S. Patent No. 10,842,780 claims the extended-release formulation | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
